Formulation and Evaluation of Flare Responsive Injectable Hydrogel

Abstract

Purpose-The formulation of injectable hydrogel aims to treat arthritis, which is one of the most common inflammatory autoimmune disorders of joints. The use of conventional drugs like NSAIDs in the treatment has various side effects. The main advantage of this dosage form is that it will release the drug depending on the flare. More drugs will release when disease activity is more. It avoids first pass metabolism. Use of newlinedrug in combination gives synergistic effect which leads to reduction in dose as well newlineas side effects. Method- Using the statistical model, one formulation is optimized where the percent drug release and viscosity is considered. Hyaluronic acid, TG18 are the polymers which are used for the formulation of injectable hydrogel containing Teriflunomide and honey bee venom as active ingredients. This hydrogel is prepared by the physical cross linking method. Various evaluation parameters such as physical properties, pH, viscosity, swelling studies, assay, in vitro drug release and stability testing were carried out. Result- No considerable changes occurred in either physicochemical properties or drug content and release of drug after exposure to accelerated conditions of temperature newline(40 ± 2oC) and humidity conditions (75 ±5%RH). Hyaluronic acid and TG18 was found to be suitable polymer for injectable hydrogel formulation based on in vitro evaluation studies. In vivo studies shows good antiarthritic activity analyzed by freunds adjuvant Model. Conclusion- The results suggest the feasibility of the hydrogel formulaton of Teriflunomide and bee venom. The formulation of these injectable hydrogel containing TRF and HBV evaluated considering various evaluation parameter. Dosage form development of hydrogel containing TRF and HBV was done successfully using DoE. Both the newlineformulations show good in vivo activity and in in vivo in vitro correlation.